Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A great economist (no, not that one) once said:
Only down 26.15% today!
Things are looking up!
At this rate Purdue will be hiring you and your little circle jerk of stock pimps to promote their wonder drug OxyContin.
Keep up the good work, chaps!
Earlier today, IPIX hit an all-time low of $0.0101, that is a fraction over 1 cent.
Trips will be here sooner rather than later.
Interesting, as it concerns OTC stocks:
"SEC Charges Archipelago Trading Services with Failing to File Suspicious Activity Reports
FOR IMMEDIATE RELEASE
2023-164
Washington D.C., Aug. 29, 2023 —
The Securities and Exchange Commission today announced charges against Archipelago Trading Services Inc. (ATSI) for failing to file hundreds of legally required reports of suspicious financial transactions, known as Suspicious Activity Reports (SARs), between August 2012 and September 2020. The charges were related to transactions in over-the-counter (OTC) securities executed on ATSI’s alternative trading system (ATS). ATSI, a Chicago-based broker-dealer, has agreed to pay $1.5 million to settle the charges.
According to the SEC’s order, ATSI’s sole line of business is to operate an OTC equity securities ATS, known as Global OTC, which is used by broker-dealers to execute trades in OTC securities. Global OTC plays a significant role in executing trades of microcap and penny stock securities, which are not listed on any national exchange and tend to be high-risk securities. Despite thousands of high-risk microcap and penny stock securities transactions executed daily on Global OTC, the SEC order found that ATSI failed to establish an anti-money laundering surveillance program for its transactions until September 2020. ATSI therefore failed to surveil transactions executed on Global OTC for possible red flags regarding suspicious manipulative trading activity, including possible spoofing, layering, wash trading, and pre-arranged trading. As a result, the SEC’s order found, ATSI failed to file at least 461 SARs, most of which involved microcap or penny stock securities.
“All SEC-registered broker-dealers have the responsibility to comply with the requirements of the Bank Secrecy Act, including the obligation to file SARs,” said Daniel R. Gregus, Director of the SEC’s Chicago Regional Office. “When firms like ATSI fail to investigate red flags, especially those involving higher-risk microcap and penny stock securities, they put the investing public at risk.”
The SEC’s order finds that ATSI violated Section 17(a) of the Securities Exchange Act and Rule 17a-8. Without admitting or denying the SEC’s findings, ATSI agreed to a censure and a cease-and-desist order in addition to the $1.5 million penalty.
The SEC’s investigation was conducted by Ashley Dalmau-Holmes and Kristin Pauley under the supervision of Anne C. McKinley and Kathryn A. Pyszka of the SEC’s Chicago Regional Office, with assistance by SEC’s Bank Secrecy Act Review Group and Alexander Lefferts in the SEC’s Office of Investigative and Market Analytics. The examination that led to the investigation was conducted by Joseph Atatsi, Stephanie Fischer Bennett, Joon Kwak, Thomas Meier, and Jennifer Spicher of the SEC’s Division of Examinations."
https://www.sec.gov/news/press-release/2023-164
These two statements are inherently contradictory, as anyone who understands the regulatory pathwayS (note the plural) for medical devices will know.
1) “BeaMed is on track to submit, in Q2 2024, the System for potential FDA approval via the 510(k) regulatory pathway.”
2) “StingRay system is to commercialize a novel technology to treat previous inoperable cases of epilepsy and improve outcomes in other surgical-based oncology procedures. It’s exciting to think that in approximately one year this may be a reality.”
While this contradiction is evident to anybody with a modicum of knowledge or indeed to anyone prepared to conduct a few minutes of elementary DD, I'm sure it will remain out of the intellectual capacity of anyone still believing that IPIX is a legitimate enterprise.
But I will explain it on polite request if necessary.
You’re welcome.
Only 24% down for the day??
You and your sorry group of would-be stock penny pimps are losing your normal reverse Midas touch.
At this rate it’ll take weeks before your sterling efforts drive it down below the trips!
Keep up the good work, though!
Still a scam run by Canadian mafiosi, though.
As none of the IPIX aficionados here can be bothered to actually do any research, and similarly do not appear to understand elementary organic chemistry, I can answer your question:
Compound 30 is not brilacidin.
An example of an n-heptyl group (it just means a group with a hydrocarbon backbone with 7 carbon atoms, including a (CH3)C group:
And here is an arginine residue:
I'm sure all the IPIX mavens who got all excited can see that actually brilacidin has no n-heptyl group.
I'm sure you can all work out the arginine residue bit for yourself.*
You're welcome.
* Just kidding - I know you can't. Brilacidin does in fact have two arginine residues, but it's not Compound 30.
This much is (partly) true:
Try Googling the original;
Franklin-Andrews-Kramer-and-Edelstein
LOL.
LOL!
Did you actually read that link??
Global Calumny Fund.
There’s no one as gullible as an IPIX dupe.
Don’t call me surly.
Fixed it for you:
Because Leo is as corrupt as the truthful posters portray, he's given $4 million of shareholders’ money away to get a Golden Parachute deal in the form of a handsome backhander from some bottom feeding would-be MedTech company based handily out of the reach of the SEC and DoJ.
You’re welcome.